News

Select Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
May 22, 2025 6:00 AM
EDT
2025
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
Download
May 12, 2025 6:00 AM
EDT
2025
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Download
May 5, 2025 6:00 AM
EDT
2025
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
Download
April 30, 2025 6:00 AM
EDT
2025
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
Download
April 29, 2025 6:00 AM
EDT
2025
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
Download
February 27, 2025 6:00 AM
EST
2025
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
Download
February 20, 2025 4:05 PM
EST
2025
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
Download
November 18, 2024 5:53 PM
EST
2024
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Download
November 15, 2024 6:00 AM
EST
2024
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
Download
November 14, 2024 6:00 AM
EST
2024
Aurinia to Participate in Jefferies London Healthcare Conference
Download
November 7, 2024 6:10 AM
EST
2024
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
Download
November 7, 2024 6:00 AM
EST
2024
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
Download
October 30, 2024 4:05 PM
EDT
2024
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
Download
October 11, 2024 6:00 AM
EDT
2024
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Download
September 24, 2024 8:10 AM
EDT
2024
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
Download
September 13, 2024 6:00 AM
EDT
2024
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
Download
September 12, 2024 4:05 PM
EDT
2024
Aurinia Announces Board Restructuring
Download
September 5, 2024 6:00 AM
EDT
2024
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
Download
August 28, 2024 6:00 AM
EDT
2024
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Download
August 1, 2024 6:00 AM
EDT
2024
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
Download
July 19, 2024 6:00 AM
EDT
2024
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
Download
July 2, 2024 6:00 AM
EDT
2024
Aurinia to Participate in Upcoming Investor Healthcare Conferences
Download
June 14, 2024 12:16 PM
EDT
2024
Aurinia Announces 2024 Annual General Meeting Results
Download
June 5, 2024 6:00 AM
EDT
2024
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
Download
June 4, 2024 5:30 PM
EDT
2024
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
Download
No Results Found
Please try different keywords or filters.

Email Alerts

By providing your email address above, you are providing consent to Aurinia Pharmaceuticals Inc. to send you the requested Investor Email Alert updates. For information on how we protect your information, please refer to our Privacy Policy.
Thank you! Your message has been sent!
Oops! There was an error with your submission.